ArticleNature communications2020
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer.British journal of cancer · 2026Article
- [Efficacy of CD4/TGF-β bispecific antibody in a mouse model of peritoneal metastasis of malignant melanoma].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Clinical applications and future perspectives of circulating tumor cells in solid tumors.Discover oncology · 2026Review
- Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology.Journal of experimental & clinical cancer research : CR · 2026Review
- Advancements in Circulating Tumor Cell Expansion Ex Vivo: A Matured Technology?Methods in molecular biology (Clifton, N.J.) · 2026Article
- GSTA1 deficiency drives neuroendocrine differentiation via TNFRSF13B/c-FOS/CHGA axis in prostate cancer.International journal of biological sciences · 2026Article
- Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide.Cell death discovery · 2025Article
- Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product.Molecular oncology · 2025Article
- Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients.Molecular oncology · 2025Article
- Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.Seminars in immunopathology · 2025Review
- Article
- Clinical applications of circulating tumor cells in patients with solid tumors.Clinical & experimental metastasis · 2024Review
- Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.Clinical and translational medicine · 2024Review
- Dissemination of Circulating Tumor Cells in Breast and Prostate Cancer: Implications for Early Detection.Endocrinology · 2024Review
- Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.Cancer cell · 2023Article
- Patient-derived tumor models and their distinctive applications in personalized drug therapy.Mechanobiology in medicine · 2023Review
- Clinical application of circulating tumor cells.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.Molecular cancer · 2023Article
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- The future of patient-derived xenografts in prostate cancer research.Nature reviews. Urology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformation of castration-resistant prostate cancer (CRPC) into an aggressive neuroendocrine disease (CRPC-NE) represents a major clinical challenge and experimental models are lacking. A CTC-derived eXplant (CDX) and a CDX-derived cell line are established using circulating tumor cells (CTCs) obtained by diagnostic leukapheresis from a CRPC patient resistant to enzalutamide. The CDX and the derived-cell line conserve 16% of primary tumor (PT) and 56% of CTC mutations, as well as 83% of PT copy-number aberrations including clonal TMPRSS2-ERG fusion and NKX3.1 loss. Both harbor an androgen receptor-null neuroendocrine phenotype, TP53, PTEN and RB1 loss. While PTEN and RB1 loss are acquired in CTCs, evolutionary analysis suggest that a PT subclone harboring TP53 loss is the driver of the metastatic event leading to the CDX. This CDX model provides insights on the sequential acquisition of key drivers of neuroendocrine transdifferentiation and offers a unique tool for effective drug screening in CRPC-NE management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.